Cancer BiologyAmerican Journal of Cancer ResearchPeer-reviewed
TRAIL receptor agonist TLY012 in combination with PD-1 inhibition promotes tumor regression in an immune-competent mouse model of pancreatic ductal adenocarcinoma
Anna D. Louie, Kelsey E. Huntington, Young Shin Lee…·Wafik S. El‐Deiry
This study shows that combining TLY012 with PD-1 inhibition reduces PDAC tumor growth in mice by enhancing proinflammatory cytokines and immune cell infiltration.
3 citations